| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
BRIEF REPORT |
Section on Medical Neuroendocrinology, Reproductive Biology, and Medicine Branch (F.M.B., J.J.T., K.T.A., K.P.), National Institute of Child Health and Human Development; Clinical Neurocardiology Section (G.E.), National Institute of Neurological Disorders and Stroke; and Urologic Oncology Branch (W.M.L.), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1109; and Division of Molecular Diagnostics (J.A.K.), Departments of Pathology and Human Genetics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213
Address all correspondence and requests for reprints to: Karel Pacak, M.D., Ph.D., D.Sc.., Building 10, CRC, Room 1E-1-3140, 10 Center Drive, MSC-1109, Bethesda, Maryland 20892-1109. E-mail: karel{at}mail.nih.gov.
Context: Adrenal and extraadrenal paragangliomas are tumors of chromaffin cells that are usually benign but that may also develop into malignant disease. Mutations of the gene for succinate dehydrogenase subunit B (SDHB) are associated with a high risk of malignancy, but establishing the precise contribution requires relatively large numbers of patients with well-defined malignancy.
Objective: We assessed the prevalence of SDHB mutations in a series of patients with malignant paraganglioma.
Design: SDHB mutation testing was carried out in 44 consecutive patients with malignant paraganglioma. Clinical characteristics of patients with malignant disease due to SDHB mutations were compared with those without mutations.
Results: Pathogenic SDHB mutations were found in 13 of the 44 patients (30%). Close to one third of patients had metastases originating from an adrenal primary tumor, compared with a little over two thirds from an extraadrenal tumor. Among the latter patients, the frequency of SDHB mutations was 48%.
Conclusion: This study establishes that missense, nonsense, frameshift, and splice site mutations of the SDHB gene are associated with about half of all malignancies originating from extraadrenal paragangliomas. The high frequency of SDHB germline mutations among patients with malignant disease, particularly when originating from an extraadrenal paraganglioma, may justify a high priority for SDHB germline mutation testing in these patients.
This article has been cited by other articles:
![]() |
H. P. H. Neumann and C. Eng The Approach to the Patient with Paraganglioma J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2677 - 2683. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J L M Timmers, A.-P. Gimenez-Roqueplo, M. Mannelli, and K. Pacak Clinical aspects of SDHx-related pheochromocytoma and paraganglioma Endocr. Relat. Cancer, June 1, 2009; 16(2): 391 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mannelli, M. Castellano, F. Schiavi, S. Filetti, M. Giacche, L. Mori, V. Pignataro, G. Bernini, V. Giache, A. Bacca, et al. Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1541 - 1547. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cascon, G. Pita, N. Burnichon, I. Landa, E. Lopez-Jimenez, C. Montero-Conde, S. Leskela, L. J. Leandro-Garcia, R. Leton, C. Rodriguez-Antona, et al. Genetics of Pheochromocytoma and Paraganglioma in Spanish Patients J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1701 - 1705. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jimenez, M. E. Cabanillas, L. Santarpia, E. Jonasch, K. L. Kyle, E. A. Lano, S. F. Matin, R. F. Nunez, N. D. Perrier, A. Phan, et al. Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 386 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Hahn, M. Reckova, L. Cheng, L. A. Baldridge, O. W. Cummings, and C. J. Sweeney Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate J. Clin. Oncol., January 20, 2009; 27(3): 460 - 463. [Full Text] [PDF] |
||||
![]() |
B E Baysal Clinical and molecular progress in hereditary paraganglioma J. Med. Genet., November 1, 2008; 45(11): 689 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu Pheochromocytoma: Current Approaches and Future Directions Oncologist, July 1, 2008; 13(7): 779 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Cascon, I Landa, E Lopez-Jimenez, A Diez-Hernandez, M Buchta, C Montero-Conde, S Leskela, L J Leandro-Garcia, R Leton, C Rodriguez-Antona, et al. Molecular characterisation of a common SDHB deletion in paraganglioma patients J. Med. Genet., April 1, 2008; 45(4): 233 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Zelinka, H. J L M Timmers, A. Kozupa, C. C Chen, J. A Carrasquillo, J. C Reynolds, A. Ling, G. Eisenhofer, I. Lazurova, K. T Adams, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations Endocr. Relat. Cancer, March 1, 2008; 15(1): 311 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Amar, E. Baudin, N. Burnichon, S. Peyrard, S. Silvera, J. Bertherat, X. Bertagna, M. Schlumberger, X. Jeunemaitre, A.-P. Gimenez-Roqueplo, et al. Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3822 - 3828. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Korpershoek, B.-J. Petri, F. H van Nederveen, W. N M Dinjens, A. A Verhofstad, W. W de Herder, S. Schmid, A. Perren, P. Komminoth, and R. R de Krijger Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma Endocr. Relat. Cancer, June 1, 2007; 14(2): 453 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cleary, J. K Phillips, T.-T. Huynh, K. Pacak, A. G Elkahloun, J. Barb, R. A Worrell, D. S Goldstein, and G. Eisenhofer Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome J. Endocrinol., May 1, 2007; 193(2): 225 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Havekes, E. P. M. Corssmit, J. C. Jansen, A. G. L. van der Mey, A. H. J. T. Vriends, and J. A. Romijn Malignant Paragangliomas Associated with Mutations in the Succinate Dehydrogenase D Gene J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1245 - 1248. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. L. M. Timmers, A. Kozupa, G. Eisenhofer, M. Raygada, K. T. Adams, D. Solis, J. W. M. Lenders, and K. Pacak Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with Succinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 779 - 786. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |